Review: Thyroid cancer: Emerging role for targeted therapies

Keyphrases

• Targeted Therapy 100%
• Thyroid Cancer 100%
• Differentiated Thyroid Cancer 60%
• Anaplastic Thyroid Cancer 60%
• Medullary Thyroid Carcinoma 60%
• Clinical Trials 40%
• Tumor 40%
• Signaling Pathway 20%
• Recent Advances 20%
• Tyrosine Kinase Inhibitor 20%
• Standard of Care 20%
• Malignancy 20%
• Poor Prognosis 20%
• Most Common Form 20%
• Combined Modality Therapy 20%
• Angiogenesis 20%
• Solid Tumors 20%
• Standard-of-care Therapy 20%
• Systemic Therapy 20%
• Histology 20%
• Clinical Behavior 20%
• Drug-resistant Cancer 20%
• Papillary Thyroid Carcinoma 20%
• Human Thyroid Cancer 20%
• Limited Treatment Options 20%
• Favorable Outcome 20%
• Targeted Molecular Therapy 20%
• New Standards 20%
• Radioactive Iodine 20%
• Iodine 20%
• Carcinoma Thyroid 20%
• Indolent Tumor 20%
• Iodine-refractory 20%

Medicine and Dentistry

• Targeted Therapy 100%
• Thyroid Cancer 100%
• Neoplasm 60%
• Anaplastic Thyroid Carcinoma 60%
• Differentiated Thyroid Cancer 60%
• Thyroid Medullary Carcinoma 60%
• Clinical Trial 40%
• Cancer 40%
• Clinician 20%
• Angiogenesis 20%
• Solid Malignant Neoplasm 20%
• Cell Signaling Pathway 20%
• Papillary Thyroid Cancer 20%
• Tyrosine-Kinase Inhibitor 20%
• Radioactive Iodine 20%
• Molecularly Targeted Therapy 20%
• Systemic Therapy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Thyroid Cancer 100%
• Neoplasm 60%
• Differentiated Thyroid Cancer 60%
• Anaplastic Thyroid Carcinoma 60%
• Thyroid Medullary Carcinoma 60%
• Clinical Trial 40%
• Protein Tyrosine Kinase Inhibitor 20%
• Solid Malignant Neoplasm 20%
• Thyroid Papillary Carcinoma 20%
• Radioactive Iodine 20%